Experiences of Introducing New Drugs for Drug-Resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017–2019

Journal Article
  • E. Tesema
  • F. Wares
  • A. Bedru
  • C. Negeri
  • Y. Molla
  • D. Gemechu
  • A. Kassa
  • F. Tsegaye
  • L. Taye
Public Health Action
June 2021; 11 (2): 50-52(3). DOI: https://doi.org/10.5588/pha.20.0065.

Abstract

BACKGROUND: Drug-resistant TB (DR-TB) remains a major public health concern. DR-TB patient data from ALERT (All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre) Hospital, Addis Ababa, Ethiopia, who received bedaquiline (BDQ) and/or delamanid (DLM) containing regimens were analysed.

RESULTS: From 2017 to 2019, 51 DR-TB patients were enrolled. Of 33 patients, 31 (93.9%) had culture converted at 6 months. Of those with final outcomes, 77% (n = 10) were cured. Thirty (58.8%) developed adverse events, the most frequent of which were gastrointestinal disorders (70%), haematological disorders (16.7%) and QTc prolongation (16.7%). Twenty patients discontinued the offending drug permanently.

CONCLUSION: With close monitoring, introduction of new DR-TB regimens brought good early results, which encouraged wider programmatic implementation in Ethiopia.